CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma

Targeted therapy for lung squamous cell carcinoma (LUSC) remains a challenge due to the lack of robust targets. Here, we identified MECOM as a candidate of therapeutic target for LUSC by screening 38 genes that were commonly amplified in three pairs of primary tumors and patient-derived xenografts (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuanyuan, Kang, Bin, Li, Shaolei, Xie, Guoyun, Bi, Jiwang, Li, Fuqiang, An, Guo, Liu, Bing, Li, Jing, Shen, Yue, Xu, Xun, Yang, Huanming, Yang, Yue, Gu, Ying, Wu, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637721/
https://www.ncbi.nlm.nih.gov/pubmed/35733338
http://dx.doi.org/10.1016/j.ymthe.2022.06.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637721/
https://www.ncbi.nlm.nih.gov/pubmed/35733338
http://dx.doi.org/10.1016/j.ymthe.2022.06.011

Ejemplares similares